
## Andrea V Margulis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1143492/publications.pdf Version: 2024-02-01



ANDREA V MARCHUS

#	Article	IF	CITATIONS
1	Perinatal pharmacoepidemiology: How often are key methodological elements reported in publications?. Pharmacoepidemiology and Drug Safety, 2022, 31, 61-71.	1.9	4
2	Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiology and Drug Safety, 2021, 30, 237-247.	1.9	15
3	A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Current Medical Research and Opinion, 2021, 37, 867-877.	1.9	3
4	Improving the Quality of Observational Data: Registries of Validated Outcomes and Other Patient Events. Epidemiology, 2021, 32, 661-663.	2.7	2
5	Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Safety, 2021, 44, 899-915.	3.2	6
6	The Role of Congenital Cytomegalovirus Infection in Adverse Birth Outcomes: A Review of the Potential Mechanisms. Viruses, 2021, 13, 20.	3.3	28
7	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatology, The, 2020, 2, e698-e711.	3.9	117
8	Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS ONE, 2019, 14, e0214180.	2.5	25
9	Drug Safety in Pregnancy: Review of Study Approaches Requested by Regulatory Agencies. Current Epidemiology Reports, 2019, 6, 380-389.	2.4	3
10	Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive Bladder. Epidemiology, 2019, 30, e8-e9.	2.7	0
11	Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 612-619.	2.5	6
12	Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy, 2018, 38, 628-637.	2.6	15
13	Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. European Journal of Clinical Pharmacology, 2018, 74, 193-199.	1.9	12
14	Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. Epidemiology, 2018, 29, 308-313.	2.7	51
15	Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. Epidemiology, 2018, 29, e41-e42.	2.7	15
16	Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS ONE, 2018, 13, e0204456.	2.5	15
17	Ophthalmic nepafenac use in the Netherlands and Denmark. Acta Ophthalmologica, 2017, 95, 509-517.	1.1	8
18	Risk Factors for RSV Hospitalization in Healthy Preterm Infants. Pediatric Infectious Disease Journal, 2017, 36, 696-696.	2.0	3

ANDREA V MARGULIS

#	Article	IF	CITATIONS
19	The Safety of Medications in Pregnant Women: An Opportunity to Use Database Studies. Pediatrics, 2017, 140, .	2.1	16
20	Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. Pharmacotherapy, 2017, 37, 673-683.	2.6	11
21	Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States. Infectious Diseases and Therapy, 2017, 6, 477-486.	4.0	20
22	Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis. Drugs - Real World Outcomes, 2017, 4, 139-149.	1.6	15
23	Frequentist and Bayesian Meta-Analysis of Risk Factors for Respiratory Syncytial Virus Hospitalization in Preterm Infants. Value in Health, 2016, 19, A174.	0.3	Ο
24	Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants. Pediatric Infectious Disease Journal, 2016, 35, e229-e238.	2.0	37
25	Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC Cardiovascular Disorders, 2016, 16, 14.	1.7	28
26	Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results. Pharmacoepidemiology and Drug Safety, 2015, 24, 335-342.	1.9	56
27	Effects of gestational age at enrollment in pregnancy exposure registries. Pharmacoepidemiology and Drug Safety, 2015, 24, 343-352.	1.9	17
28	Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank. Clinical Epidemiology, 2014, 6, 359.	3.0	325
29	Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases. Current Epidemiology Reports, 2014, 1, 194-205.	2.4	6
30	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovascular Disorders, 2014, 14, 129.	1.7	62
31	Triggers of Spontaneous Preterm Delivery – Why Today?. Paediatric and Perinatal Epidemiology, 2014, 28, 79-87.	1.7	23
32	Patterns of Prescription of Antidepressants and Antipsychotics Across and Within Pregnancies in a Population-Based UK Cohort. Maternal and Child Health Journal, 2014, 18, 1742-1752.	1.5	43
33	Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiology and Drug Safety, 2013, 22, 16-24.	1.9	154
34	Reply to Journal Club Roundtable. American Journal of Obstetrics and Gynecology, 2013, 209, 72.	1.3	0
35	Determining the predictive value of Read codes to identify congenital cardiac malformations in the UK Clinical Practice Research Datalink. Pharmacoepidemiology and Drug Safety, 2013, 22, 1233-1238.	1.9	13
36	Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensityâ€score matched cohort in CPRD. Pharmacoepidemiology and Drug Safety, 2013, 22, 942-951.	1.9	43

#	Article	IF	CITATIONS
37	Elevated Risk of Preeclampsia in Pregnant Women With Depression: Depression or Antidepressants?. American Journal of Epidemiology, 2012, 175, 988-997.	3.4	81
38	Use of topiramate in pregnancy and risk of oral clefts. American Journal of Obstetrics and Gynecology, 2012, 207, 405.e1-405.e7.	1.3	130
39	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. Pharmacoepidemiology and Drug Safety, 2011, 20, 1088-1097.	1.9	7
40	Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiology and Drug Safety, 2009, 18, 900-909.	1.9	35
41	Effectiveness of Pediatric Antiretroviral Therapy in Resourceâ€Limited Settings: A Systematic Review and Metaâ€analysis. Clinical Infectious Diseases, 2009, 49, 1915-1927.	5.8	107